Roche launches new quantitative antibody test for COVID-19

September 18, 2020  –  Roche (Basel, Switzerland) launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark.

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the SARS-CoV-2 virus and can play an important part in characterizing a vaccine-induced immune response. Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell. The majority of current candidate vaccines aim to induce an antibody response against the spike protein.

The test is the latest addition to the comprehensive Roche diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care.

Currently, this portfolio includes molecular, serology and digital solutions which help diagnose and manage COVID-19 during the initial stages of infection, during the recovery phase, as well as following the resolution of infection.

Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA).

Learn More